Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Uxin (UXIN) EBITDA (2017 - 2025)

Uxin filings provide 9 years of EBITDA readings, the most recent being -$11.8 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 7.91% to -$11.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.6 billion, a 61.39% increase, with the full-year FY2025 number at -$36.5 million, up 21.4% from a year prior.
  • EBITDA hit -$11.8 million in Q4 2025 for Uxin, up from -$7.6 billion in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $208.8 billion in Q4 2021 to a low of -$267.7 billion in Q3 2021.
  • Median EBITDA over the past 5 years was -$8.2 million (2024), compared with a mean of -$5.4 billion.
  • Biggest five-year swings in EBITDA: surged 1289.05% in 2021 and later crashed 200364937.52% in 2024.
  • Uxin's EBITDA stood at $208.8 billion in 2021, then crashed by 100.0% to -$13193.0 in 2022, then grew by 17.93% to -$10827.0 in 2023, then crashed by 100786.67% to -$10.9 million in 2024, then fell by 7.91% to -$11.8 million in 2025.
  • The last three reported values for EBITDA were -$11.8 million (Q4 2025), -$7.6 billion (Q3 2025), and -$9.4 million (Q2 2025) per Business Quant data.